Madrigal Pharmaceuticals Q4 Earnings Call Highlights

Core Insights - The company reported significant patient growth and net sales for its product Rezdiffra, indicating strong market performance and expansion opportunities [1][3][4] Patient Growth and Market Performance - The patient base for Rezdiffra increased to over 36,250 by the end of Q4 2025, up from over 29,500 at the end of Q3 2025, reflecting a net of new starts and discontinuations [1] - Rezdiffra achieved nearly $958 million in net sales during its first full year, with Q4 2025 net sales reaching $321 million, more than triple the prior-year quarter [3][7] - The U.S. F2/F3 target population has expanded by approximately 50% since the end of 2023, with expectations for continued double-digit growth in the market [7] Commercial Strategy and Pipeline Development - The company is focused on building the market from scratch through prescriber education, establishing care pathways, and expanding prescriber access [2] - Madrigal is developing a combination-focused pipeline with more than 10 programs, including an oral GLP-1 candidate and a DGAT2 inhibitor, with resmetirom as the anchor [6][13] - The company aims to expand into compensated MASH cirrhosis (F4c), which could potentially double the commercial opportunity if approved [9] Financial Outlook and Expenses - Management expects gross-to-net to rise to the high-30% range in 2026 due to payer contracting, with full-year 2025 gross-to-net results at the low end of the previously discussed 20%-30% range [5][17] - R&D expenses for Q4 2025 were reported at $116.3 million, with full-year expenses at $388.5 million, primarily due to business development upfront payments [23] - SG&A expenses for Q4 2025 were $240 million, reflecting ongoing support for the Rezdiffra launch [23] Cash Position and International Expansion - The company ended Q4 2025 with approximately $988.6 million in cash and equivalents, providing ample resources for ongoing launch and pipeline advancement [20] - International contributions, particularly from Germany, were negligible in 2025, with expectations for limited ex-U.S. contributions in 2026, focusing on the U.S. as the primary growth market [20]